To include your compound in the COVID-19 Resource Center, submit it here.

Pfizer sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Bosulif bosutinib from Pfizer to treat chronic, accelerated and blast phase Philadelphia chromosome-positive

Read the full 266 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE